Spruce Biosciences, Inc. (SPRB)

NASDAQ: SPRB · IEX Real-Time Price · USD
1.37
0.01 (0.74%)
May 27, 2022 10:32 AM EDT - Market open
Market Cap32.19M
Revenue (ttm)n/a
Net Income (ttm)-44.17M
Shares Out23.49M
EPS (ttm)-1.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,297
Open1.31
Previous Close1.36
Day's Range1.31 - 1.37
52-Week Range1.25 - 15.08
Betan/a
AnalystsBuy
Price Target9.35 (+582.5%)
Earnings DateMay 11, 2022

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for...

IndustryBiotechnology
IPO DateOct 9, 2020
Employees16
Stock ExchangeNASDAQ
Ticker SymbolSPRB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is 9.35, which is an increase of 582.48% from the latest price.

Price Target
$9.35
(582.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

2 weeks ago - Business Wire

Spruce Biosciences to Participate in May Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

3 weeks ago - Business Wire

Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C.

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

1 month ago - Business Wire

Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

2 months ago - Business Wire

Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

2 months ago - Business Wire

Spruce Biosciences to Participate in March Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

2 months ago - Business Wire

Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

3 months ago - Business Wire

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

4 months ago - Business Wire

Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

4 months ago - Business Wire

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Other symbols:APTOCELUCNSPCYAD
4 months ago - Zacks Investment Research

Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk

Penny stocks with high short interest gaining plenty of attention in the stock market today. The post Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk appeared first on Penny Stocks to Bu...

Other symbols:FTFT
4 months ago - PennyStocks

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now

5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?

Other symbols:IINNPLXSELBTELL
5 months ago - PennyStocks

Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme...

5 months ago - Zacks Investment Research

Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

6 months ago - Business Wire

Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

6 months ago - Business Wire

Spruce Biosciences Appoints Mike Grey as Interim CEO

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences Appoints Mike Grey as Interim CEO

6 months ago - Business Wire

Spruce Biosciences to Participate in September Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in September Investor Conferences

8 months ago - Business Wire

Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day

9 months ago - Business Wire

Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary Syndrome

Late-stage biopharmaceutical company Spruce Biosciences Inc (NASDAQ: SRPB) reported financial results for the second quarter ended June 30, 2021 and announced that it has submitted an investigational ne...

9 months ago - Benzinga

Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...

9 months ago - Business Wire

Why Earnings Season Could Be Great for Spruce Biosciences (SPRB)

Spruce Biosciences is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

Other symbols:FSTXHALOKNTERUBY
9 months ago - Zacks Investment Research

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors.

Dr. Ways' Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce's Goal to Expand Portfolio of Indications for Tildacerfont  San Francisco, Calif. ...

11 months ago - Benzinga

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors

11 months ago - Business Wire

Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and...

Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomarkers

11 months ago - Benzinga